Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 4/2016

01-04-2016 | Movement Disorders (S Fox, Section Editor)

Integrated Approach for Pain Management in Parkinson Disease

Authors: Christian Geroin, Marialuisa Gandolfi, Veronica Bruno, Nicola Smania, Michele Tinazzi

Published in: Current Neurology and Neuroscience Reports | Issue 4/2016

Login to get access

Abstract

Pain, one of the most frequent nonmotor symptoms of Parkinson disease (PD), is recognized as an important component of the illness that adversely affects patient quality of life. The aims of this review are to summarize the current knowledge on the clinical assessment and to provide a detailed overview of the evidence-based pharmacologic and nonpharmacologic approaches to treating pain. Results of a literature search include studies investigating pain/sensory abnormalities in PD. The effects of levodopa administration, deep brain stimulation (DBS), pallidotomy, spinal cord stimulation, rehabilitation, and complementary/alternative medicine are reviewed critically. PD patients have altered pain and sensory thresholds; levodopa and DBS improve pain and change sensory abnormalities toward normal levels through antinociceptive and/or modulatory effects that remain unknown. A wide range of nonpharmacologic approaches require further investigation. A multidisciplinary approach is fundamental in managing pain syndromes in PD.
Literature
1.
Quittenbaum BH, Grahn B. Quality of life and pain in Parkinson’s disease: a controlled cross-sectional study. Parkinsonism Relat Disord. 2004;10:129–36.CrossRefPubMed
2.
Mao CJ, Chen JP, Zhang XY, Liu CF, et al. Parkinson’s disease patients with pain suffer from more severe non-motor symptoms. Neurol Sci. 2015;36:263–8.CrossRefPubMed
3.
4.
Parkinson J. An essay on the shaking palsy. London: Whittingham and Rowland; 1817.
5.
Ford B. Pain in Parkinson disease: the hidden epidemic visual rating of atrophy aids diagnostic accuracy. Nat Rev Neurol. 2009;5:242–3.CrossRefPubMed
6.
7.
Toda K, Harada T. Prevalence, classification, and etiology of pain in Parkinson’s disease: association between Parkinson’s disease and fibromyalgia or chronic widespread pain. Tohoku J Exp Med. 2010;222:1–5.CrossRefPubMed
8.••
Defazio G, Gigante A, Mancino P, Tinazzi M. The epidemiology of pain in Parkinson’s disease. J Neural Transm. 2013;120:583–6. Defazio et al. reviewed the literature on pain epidemiology in PD patients. They showed that pain affects a large population of patients and should be considered a nonmotor symptom. This study shows that different qualities of pain may be present in PD and that there is a variable relationship between pain and motor signs and the response to dopaminergic medications.CrossRefPubMed
9.
Broen MP, Braaksma MM, Patijn J, Weber WE. Prevalence of pain in Parkinson’s disease: a systematic review using the modified QUADAS tool. Mov Disord. 2012;27:480–4.CrossRefPubMed
10.
Defazio G, Berardelli A, Fabbrini G, et al. Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol. 2008;65:1191–4.CrossRefPubMed
11.
Nègre-Pagès L, Regragui W, Bouhassira D, Grandjean H, Rascol O, DoPaMiP Study Group. Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord. 2008;23:1361–9.CrossRefPubMed
12.
Zambito Marsala S, Tinazzi M, Vitaliani R, et al. Spontaneous pain, pain threshold, and pain tolerance in Parkinson’s disease. J Neurol. 2011;258:627–33.CrossRefPubMed
13.
Broetz D, Eichner M, Gasser T, Weller M, Steinbach JP. Radicular and nonradicular back pain in Parkinson’s disease: a controlled study. Mov Disord. 2007;22:853–6.CrossRefPubMed
14.
Vela L, Facca A, Lyons KE, Lieberman AN. Pain and Parkinson’s disease. Mov Disord. 2002;17:S154–5.CrossRef
15.
16.
McNamara P, Stavitsky K, Harris E, et al. Mood, side of motor symptom onset and pain complaints in Parkinson’s disease. Int J Geriatr Psychiatry. 2010;25:519–24.CrossRefPubMed
17.
Greenbaum L, Tegeder I, Barhum Y, et al. Contribution of genetic variants to pain susceptibility in Parkinson disease. Eur J Pain. 2012;9:1243–50.CrossRef
18.
19.
20.
Beiske AG, Loge JH, Rønningen A, Svensson E. Pain in Parkinson’s disease: prevalence and characteristics. Pain. 2009;141:173–7.CrossRefPubMed
21.
22.
23.
Gierthmühlen J, Arning P, Binder A, et al. Influence of deep brain stimulation and levodopa on sensory signs in Parkinson’s disease. Mov Disord. 2010;25:1195–202.CrossRefPubMed
24.
de Ciampi AD, Lefaucheur JP, Galhardoni R, et al. Subthalamic deep brain stimulation modulates small fiber-dependent sensory thresholds in Parkinson’s disease. Pain. 2012;153:1107–13.CrossRef
25.
Granovsky Y, Schlesinger I, Fadel S, Erikh I, Sprecher E, Yarnitsky D. Asymmetric pain processing in Parkinson’s disease. Eur J Neurol. 2013;20:1375–82.CrossRefPubMed
26.
Lim SY, Farrell MJ, Gibson SJ, Helme RD, Lang AE, Evans AH. Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson’s disease? Mov Disord. 2008;23:1689–95.CrossRefPubMed
27.
28.
Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, et al. Levodopa raises objective pain threshold in Parkinson’s disease: a RIII reflex study. J Neurol Neurosurg Psychiatry. 2007;78:1140–2.CrossRefPubMedPubMedCentral
29.
Perrotta A, Sandrini G, Serrao M, et al. Facilitated temporal summation of pain at spinal level in Parkinson’s disease. Mov Disord. 2011;26:442–8.CrossRefPubMed
30.
Mylius V, Engau I, Teepker M, et al. Pain sensitivity and descending inhibition of pain in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2009;80:24–8.CrossRefPubMed
31.
Brefel-Courbon C, Payoux P, Thalama C, et al. Effect of levodopa on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord. 2005;20:1557–63.CrossRefPubMed
32.
Brefel-Courbon C, Ory-Magne F, Thalamas C, Payoux P, Rascol O. Nociceptive brain activation in patients with neuropathic pain related to Parkinson’s disease. Parkinsonism Relat Disord. 2013;19:548–52.CrossRefPubMed
33.
Djaldetti R, Shifrin A, Rogowski Z, Sprecher E, Melamed E, Yarnitsky D. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology. 2004;62:2171–5.CrossRefPubMed
34.
Schestatsky P, Kumru H, Valls-Sole J, et al. Neurophysiologic study of central pain in patients with Parkinson disease. Neurology. 2007;69:2162–9.CrossRefPubMed
35.
Tinazzi M, Del Vesco C, Defazio G, et al. Abnormal processing of the nociceptive input in Parkinson’s disease: a study with CO2 laser evoked potentials. Pain. 2008;136:117–24.CrossRefPubMed
36.
Tinazzi M, Recchia S, Simonetto S, et al. Hyperalgesia and laser evoked potentials alterations in hemiparkinson: evidence for an abnormal nociceptive processing. J Neurol Sci. 2009;276:153–8.CrossRefPubMed
37.
Tinazzi M, Recchia S, Simonetto S, et al. Muscular pain in Parkinson’s disease and nociceptive processing assessed with CO2 laser-evoked potentials. Mov Disord. 2010;25:213–20.CrossRefPubMed
38.
Mylius V, Brebbermann J, Dohmann H, Engau I, Oertel WH, Möller JC. Pain sensitivity and clinical progression in Parkinson’s disease. Mov Disord. 2011;26:2220–5.CrossRefPubMed
39.
Conte A, Khan N, Defazio G, Rothwell JC, Berardelli A. Pathophysiology of somatosensory abnormalities in Parkinson disease. Nat Rev Neurol. 2013;9:687–97.CrossRefPubMed
40.
Reichling DB, Levine JD. Pain and death: neurodegenerative disease mechanisms in the nociceptor. Ann Neurol. 2011;69:13–21.CrossRefPubMed
41.
Nolano M, Provitera V, Estraneo A, et al. Sensory deficit in Parkinson’s disease: evidence of a cutaneous denervation. Brain. 2008;131:1903–11.CrossRefPubMed
42.
Kanda T, Tsukagoshi H, Oda M, Miyamoto K, Tanabe H. Changes of unmyelinated nerve fibers in sural nerve in amyotrophic lateral sclerosis, Parkinson’s disease and multiple system atrophy. Acta Neuropathol. 1996;91:145–54.CrossRefPubMed
43.
Dellapina E, Gerdelat-Mas A, Ory-Magne F, et al. Apomorphine effect on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord. 2011;26:153–7.CrossRefPubMed
44.
Nandhagopal R, Troiano AR, Mak E, Schulzer M, Bushnell MC, Stoessl AJ. Response to heat pain stimulation in idiopathic Parkinson’s disease. Pain Med. 2010;11:834–40.CrossRefPubMed
45.
Spielberger S, Wolf E, Kress M, Seppi K, Poewe W. The influence of deep brain stimulation on pain perception in Parkinson’s disease. Mov Disord. 2011;26:1367–8.CrossRefPubMed
46.
Dellapina E, Ory-Magne F, Regragui W, et al. Effect of subthalamic deep brain stimulation on pain in Parkinson’s disease. Pain. 2012;153:2267–73.CrossRefPubMed
47.
Vela L, Cano-de-la-Cuerda R, Fil A, Muñoz-Hellín E, Ortíz-Gutiérrez R, Macías-Macías Y, et al. Thermal and mechanical pain thresholds in patients with fluctuating Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:953–7.CrossRefPubMed
48.
Marques A, Chassin O, Morand D, et al. Central pain modulation after subthalamic nucleus stimulation: a crossover randomized trial. Neurology. 2013;81:633–40.CrossRefPubMed
49.
Chen Y, Mao CJ, Li SJ, et al. Quantitative and fiber-selective evaluation of pain and sensory dysfunction in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2015;21:361–5.CrossRefPubMed
50.
Vela L, Lyons KE, Singer C, Lieberman AN. Pain-pressure threshold in patients with Parkinson’s disease with and without dyskinesia. Parkinsonism Relat Disord. 2007;13:189–92.CrossRefPubMed
51.
Lee MA, Walker RW, Hildreth TJ, Prentice WM. A survey of pain in idiopathic Parkinson’s disease. J Pain Symptom Manag. 2006;32:462–9.CrossRef
52.
Reuter I, Mehnert S, Leone P, Kaps M, Oechsner M, Engelhardt M. Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson’s disease. J Aging Res. 2011;2011, 232473.CrossRefPubMedPubMedCentral
53.
Donoyama N, Ohkoshi N. Effects of traditional Japanese massage therapy on various symptoms in patients with Parkinson’s disease: a case-series study. J Altern Complement Med. 2012;18:294–9.CrossRefPubMed
54.
Fénelon G, Goujon C, Gurruchaga JM, et al. Spinal cord stimulation for chronic pain improved motor function in a patient with Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:213–4.CrossRefPubMed
55.
Oshima H, Katayama Y, Morishita T, et al. Subthalamic nucleus stimulation for attenuation of pain related to Parkinson disease. J Neurosurg. 2012;116:99–106.CrossRefPubMed
56.
Wolz M, Hauschild J, Koy J, et al. Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:994–7.CrossRefPubMed
57.
Cury RG, Galhardoni R, Fonoff ET, et al. Effects of deep brain stimulation on pain and other nonmotor symptoms in Parkinson disease. Neurology. 2014;83:1403–9.CrossRefPubMed
58.•
Kim YE, Lee WW, Yun JY, Yang HJ, Kim HJ, Jeon BS. Musculoskeletal problems in Parkinson’s disease: neglected issues. Parkinsonism Relat Disord. 2013;19:666–9. Kim et al. identified the prevalence and clinical features of musculoskeletal problems in patients with PD in their study enrolling 400 PD patients and 138 age- and sex-matched controls. They found a significantly greater prevalence of musculoskeletal problems in the PD group than in the control group (66.3% vs. 45.7%). The body parts commonly involved were the low back, knees, and shoulders. This study highlights the importance of evaluating musculoskeletal problems in people with PD.CrossRefPubMed
59.
Sürücü O, Baumann-Vogel H, Uhl M, Imbach LL, Baumann CR. Subthalamic deep brain stimulation versus best medical therapy for L-dopa responsive pain in Parkinson’s disease. Pain. 2013;154:1477–9.CrossRefPubMed
60.•
Jung YJ, Kim HJ, Jeon BS, Park H, Lee WW, Paek SH. An 8-year follow-up on the effect of subthalamic nucleus deep brain stimulation on pain in Parkinson disease. JAMA Neurol. 2015;72:504–10. Jung et al. evaluated the long-term effects of STN-DBS in patients with PD and pain. This study demonstrated that STN-DBS can improve pain and that the effects persist after 8 years of follow-up.CrossRefPubMed
61.
Kim HJ, Jeon BS, Lee JY, Paek SH, Kim DG. The benefit of subthalamic deep brain stimulation for pain in Parkinson disease: a 2-year follow-up study. Neurosurgery. 2012;70:18–23.CrossRefPubMed
62.
Honey CR, Stoessl AJ, Tsui JK, Schulzer M, Calne DB. Unilateral Pallidotomy for reduction of parkinsonian pain. J Neurosurg. 1999;91:198–201.CrossRefPubMed
63.
Kim HJ, Paek SH, Kim JY, et al. Chronic subthalamic deep brain stimulation improves pain in Parkinson disease. J Neurol. 2008;255:1889–94.CrossRefPubMed
64.
Pellaprat J, Ory-Magne F, Canivet C, et al. Deep brain stimulation of the subthalamic nucleus improves pain in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:662–4.CrossRefPubMed
65.
Hanagasi HA, Akat S, Gurvit H, Yazici J, Emre M. Pain is common in Parkinson’s disease. Clin Neurol Neurosurg. 2011;113:11–3.CrossRefPubMed
66.
de Rodrigues PF, Teixeira-Salmela LF, de Coelho MFCD, de Rocha BP, Cardoso F. Impact of an exercise program on physical, emotional, and social aspects of quality of life of individuals with Parkinson’s disease. Mov Disord. 2006;21:1073–7.CrossRef
67.
Shulman LM, Wen X, Weiner WJ, et al. Acupuncture therapy for the symptoms of Parkinson’s disease. Mov Disord. 2002;17:799–802.CrossRefPubMed
68.
Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society UPDRS Revision Task force. Movement Disorder Society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129–70.CrossRefPubMed
69.
Cury RG, Galhardoni R, Fonoff ET, et al. Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms. Eur J Pain. 2015.
70.
Clark WC, Yang JC, Tsui SL, Ng KF, Bennett CS. Unidimensional pain rating scales: a multidimensional affect and pain survey (MAPS) analysis of what they really measure. Pain. 2002;98:241–7.CrossRefPubMed
71.
Perez-Lloret S, Rey MV, Dellapina E, Pellaprat J, Brefel-Courbon C, Rascol O. Emerging analgesic drugs for Parkinson’s disease. Expert Opin Emerg Drugs. 2012;17:157–71.CrossRefPubMed
72.
Stacy M. The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson’s disease. J Neural Transm. 2010;117:837–46.CrossRefPubMed
73.
Nebe A, Ebersbach G. Pain intensity on and off levodopa in patients with Parkinson’s disease. Mov Disord. 2009;24:1233–7.CrossRefPubMed
74.
Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573–80.CrossRefPubMed
75.
Factor SA, Brown DL, Molho ES. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson’s disease. Mov Disord. 2000;15:167–9.CrossRefPubMed
76.
Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1990;53:96–101.CrossRefPubMedPubMedCentral
77.
Kassubek J, Chaudhuri KR, Zesiewicz T, et al. Rotigotine transdermal system and evaluation of pain inpatients with Parkinson’s disease: a post hoc analysis of the RECOVER study. BMC Neurol. 2014;14–42.
78.
Juri C, Rodriguez-Oroz M, Obeso JA. The pathophysiological basis of sensory disturbances in Parkinson’s disease. J Neurol Sci. 2010;289:60–5.CrossRefPubMed
79.
Ghoche R. The conceptual framework of palliative care applied to advanced Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:S2–5.CrossRefPubMed
80.
Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol. 2007;30:201–5.PubMed
81.
Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord. 2001;16:907–13.CrossRefPubMed
82.
Bonanni L, Thomas A, Varanese S, Scorrano V, Onofrj M. Botulinum toxin treatment of lateral axial dystonia in Parkinsonism. Mov Disord. 2007;22:2097–103.CrossRefPubMed
83.•
Tassorelli C, De Icco R, Alfonsi E, et al. Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo controlled study. Parkinsonism Relat Disord. 2014;20:1140–4. Tassorelli et al. evaluated the effects of BTX type A in reducing hyperactive trunk muscles and enhancing the rehabilitation intervention. Their preliminary data suggest that BTX type A in conjunction with a rehabilitation program may improve axial posture and trunk mobility, as well as pain symptoms. This study highlights the importance of an integrated approach to managing motor and nonmotor symptoms in PD patients.CrossRefPubMed
84.
85.
Loher TJ, Burgunder JM, Weber S, Sommerhalder R, Krauss JK. Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73:395–9.CrossRefPubMedPubMedCentral
86.
Deep-Brain Stimulation for Parkinson’s Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J Med. 2001;345:956–63.CrossRef
87.
Witjas T, Kaphan E, Régis J, et al. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson’s disease. Mov Disord. 2007;22:1729–34.CrossRefPubMed
88.
Maruo T, Saitoh Y, Hosomi K, et al. Deep brain stimulation of the subthalamic nucleus improves temperature sensation in patients with Parkinson’s disease. Pain. 2011;152:860–5.CrossRefPubMed
89.
Ogino Y, Nemoto H, Inui K, Saito S, Kakigi R, Goto F. Inner experience of pain: imagination of pain while viewing images showing painful events forms subjective pain representation in human brain. Cereb Cortex. 2007;17:1139–46.CrossRefPubMed
90.
Hodges PW. Pain and motor control: from the laboratory to rehabilitation. J Electromyogr Kinesiol. 2011;21:220–8.CrossRefPubMed
91.
Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson’s disease. J Neurosurg. 1992;76:53–61.CrossRefPubMed
92.
Oakley JC, Prager JP. Spinal cord stimulation: mechanisms of action. Spine (Phila Pa 1976). 2002;27:2574–83.CrossRef
93.
94.
Allen NE, Moloney N, van Vliet V, Canning CG. The rationale for exercise in the management of pain in Parkinson’s disease. J Parkinsons Dis. 2015.
95.
Rajendran PR, Thompson RE, Reich SG. The use of alternative therapies by patients with Parkinson’s disease. Neurology. 2001;57:790–4.CrossRefPubMed
96.
Gatchel RJ, McGeary DD, McGeary CA, Lippe B. Interdisciplinary chronic pain management: past, present, and future. Am Psychol. 2014;69:119–30.CrossRefPubMed
Metadata
Title
Integrated Approach for Pain Management in Parkinson Disease
Authors
Christian Geroin
Marialuisa Gandolfi
Veronica Bruno
Nicola Smania
Michele Tinazzi
Publication date
01-04-2016
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 4/2016
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-016-0628-7

Other articles of this Issue 4/2016

Current Neurology and Neuroscience Reports 4/2016 Go to the issue

Neurotrauma (M Kumar, Section Editor)

Cerebral Lactate Metabolism After Traumatic Brain Injury

Demyelinating Disorders (DN Bourdette and M Cameron, Section Editors)

The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis

Neurology of Systemic Diseases (J Biller, Section Editor)

Neurologic Complications of Commonly Used Drugs in the Hospital Setting

Headache (R. B. Halker, Section Editor)

Managing Migraine During Pregnancy and Lactation

Movement Disorders (S Fox, Section Editor)

Novel Approaches to Optimization of Levodopa Therapy for Parkinson’s Disease

Stroke (HP Adams, Section Editor)

The Role of Vascular Imaging in the Initial Assessment of Patients with Acute Ischemic Stroke